Northwest Biotherapeutics Inc (NWBO) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
4800 MONTGOMERY LANE BETHESDA, MD 20814 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,175 | 2,126 | 6,965 | 15,169 | 9,983 | 372 | |||
| Cash and cash equivalent | 2,175 | 2,126 | 6,965 | 15,169 | 9,983 | 372 | |||
| Other undisclosed current assets | 1,887 | 1,999 | 2,460 | 2,121 | 5,528 | 2,828 | |||
| Total current assets: | 4,062 | 4,125 | 9,425 | 17,290 | 15,511 | 3,200 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 4,187 | 4,183 | 4,189 | 4,889 | 4,489 | 4,679 | |||
| Property, plant and equipment | 16,196 | 17,278 | 13,418 | 15,027 | 1,040 | 281 | |||
| Intangible assets, net (including goodwill) | 1,918 | 1,918 | 1,918 | 1,918 | 1,918 | ||||
| Goodwill | 626 | 626 | 626 | 626 | 626 | ||||
| Intangible assets, net (excluding goodwill) | 1,292 | 1,292 | 1,292 | 1,292 | 1,292 | ||||
| Other noncurrent assets | 365 | 361 | 345 | 1,036 | 867 | 798 | |||
| Other undisclosed noncurrent assets | 2,028 | 9,074 | 171 | ||||||
| Total noncurrent assets: | 22,666 | 23,740 | 21,898 | 22,870 | 17,388 | 5,929 | |||
| TOTAL ASSETS: | 26,728 | 27,865 | 31,323 | 40,160 | 32,899 | 9,129 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 16,969 | 10,244 | 10,687 | 6,976 | 7,380 | 6,348 | |||
| Other undisclosed accounts payable and accrued liabilities | 16,969 | 10,244 | 10,687 | 6,976 | 7,380 | 6,348 | |||
| Debt | 14,186 | 3,944 | 15,403 | 7,104 | 2,437 | 5,896 | |||
| Deferred compensation liability | 207 | 7 | 2,566 | ||||||
| Derivative instruments and hedges, liabilities | 2,219 | 944 | 80,559 | 106,784 | 354,972 | 20,213 | |||
| Business combination, contingent consideration, liability | 9,578 | 9,188 | 8,668 | 8,232 | 8,275 | 7,261 | |||
| Due to related parties | ✕ | ✕ | ✕ | 66 | |||||
| Other undisclosed current liabilities | 25,115 | 20,877 | 8,122 | 4,673 | 9,360 | 1,410 | |||
| Total current liabilities: | 68,274 | 45,204 | 126,005 | 133,769 | 382,424 | 41,194 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 12,396 | 20,312 | 5,991 | 30,382 | 13,423 | 11,502 | |||
| Long-term debt, excluding current maturities | 12,396 | 20,312 | 5,991 | 25,156 | 8,507 | 6,588 | |||
| Liabilities, other than long-term debt | 4,438 | 4,454 | 4,370 | ||||||
| Operating lease, liability | 4,438 | 4,454 | 4,370 | 5,226 | 4,916 | 4,914 | |||
| Other undisclosed noncurrent liabilities | 20,600 | 4,950 | (5,226) | (4,916) | |||||
| Total noncurrent liabilities: | 37,434 | 29,716 | 10,361 | 30,382 | 13,423 | 11,502 | |||
| Total liabilities: | 105,708 | 74,920 | 136,366 | 164,151 | 395,847 | 52,696 | |||
| Temporary equity, including noncontrolling interest | 18,718 | 23,060 | |||||||
| Equity | |||||||||
| Equity, attributable to parent | (94,487) | (65,773) | (128,103) | (123,991) | (362,948) | (43,567) | |||
| Common stock | 1,328 | 1,175 | 1,068 | 948 | 830 | 614 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (79) | (79) | (79) | (79) | (79) | (10) | |||
| Additional paid in capital | 1,344,720 | 1,291,316 | 1,164,885 | 1,066,873 | 1,008,665 | 794,900 | |||
| Accumulated other comprehensive income (loss) | 3,043 | 1,536 | 3,145 | 357 | (1,148) | 836 | |||
| Accumulated deficit | (1,443,499) | (1,359,721) | (1,297,122) | (1,192,090) | (1,371,216) | (839,907) | |||
| Other undisclosed equity | 15,507 | ||||||||
| Total equity: | (78,980) | (65,773) | (128,103) | (123,991) | (362,948) | (43,567) | |||
| TOTAL LIABILITIES AND EQUITY: | 26,728 | 27,865 | 31,323 | 40,160 | 32,899 | 9,129 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 1,382 | 1,932 | 1,683 | 1,005 | 1,291 | 2,410 | ||
| Gross profit: | 1,382 | 1,932 | 1,683 | 1,005 | 1,291 | 2,410 | ||
| Operating expenses | (67,890) | (57,440) | (68,864) | (53,707) | (87,896) | (29,873) | ||
| Other undisclosed operating loss | ||||||||
| Operating loss: | (66,508) | (55,508) | (67,181) | (52,702) | (86,605) | (27,463) | ||
| Nonoperating income (expense) | (17,270) | (7,091) | (37,851) | 231,828 | (443,216) | 7,167 | ||
| Other nonoperating income (expense) | (17,270) | (7,091) | (37,851) | 231,828 | (443,216) | 7,167 | ||
| Interest and debt expense | (14,393) | (5,200) | (2,691) | (165) | (4,412) | (1,941) | ||
| Income (loss) from continuing operations before income taxes: | (98,171) | (67,799) | (107,723) | 178,961 | (534,233) | (22,237) | ||
| Income tax expense (benefit) | 1,418 | (19) | ||||||
| Other undisclosed income from continuing operations | ||||||||
| Income (loss) from continuing operations: | (96,753) | (67,818) | (107,723) | 178,961 | (534,233) | (22,237) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | 178,961 | (534,233) | (22,237) | |
| Other undisclosed net income (loss) | 5,018 | |||||||
| Net income (loss): | (96,753) | (62,800) | (107,723) | 178,961 | (534,233) | (22,237) | ||
| Other undisclosed net income attributable to parent | 12,975 | 201 | 2,691 | 165 | 4,412 | 1,941 | ||
| Net income (loss) attributable to parent: | (83,778) | (62,599) | (105,032) | 179,126 | (529,821) | (20,296) | ||
| Other undisclosed net loss available to common stockholders, basic | (1,414) | (1,774) | ||||||
| Net income (loss) available to common stockholders, basic: | (85,192) | (64,373) | (105,032) | 179,126 | (529,821) | (20,296) | ||
| Other undisclosed net income (loss) available to common stockholders, diluted | 1,774 | (239,347) | ||||||
| Net loss available to common stockholders, diluted: | (85,192) | (62,599) | (105,032) | (60,221) | (529,821) | (20,296) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (96,753) | (62,800) | (107,723) | 178,961 | (534,233) | (22,237) | ||
| Other comprehensive income (loss) | 1,507 | (1,609) | 2,788 | 1,505 | (1,984) | (164) | ||
| Comprehensive income (loss): | (95,246) | (64,409) | (104,935) | 180,466 | (536,217) | (22,401) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 11,561 | (1,573) | 2,691 | 165 | 4,412 | 1,941 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (83,685) | (65,982) | (102,244) | 180,631 | (531,805) | (20,460) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.